MX2022012404A - Composiciones que comprenden 15-hepe para tratar o prevenir trastornos hematológicos y/o enfermedades relacionadas. - Google Patents

Composiciones que comprenden 15-hepe para tratar o prevenir trastornos hematológicos y/o enfermedades relacionadas.

Info

Publication number
MX2022012404A
MX2022012404A MX2022012404A MX2022012404A MX2022012404A MX 2022012404 A MX2022012404 A MX 2022012404A MX 2022012404 A MX2022012404 A MX 2022012404A MX 2022012404 A MX2022012404 A MX 2022012404A MX 2022012404 A MX2022012404 A MX 2022012404A
Authority
MX
Mexico
Prior art keywords
hepe
compositions
treating
related diseases
hematologic disorders
Prior art date
Application number
MX2022012404A
Other languages
English (en)
Inventor
David Coughlan
John Climax
Moayed Hamza
Markus Weissbach
Original Assignee
Afimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Afimmune Ltd filed Critical Afimmune Ltd
Publication of MX2022012404A publication Critical patent/MX2022012404A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente descripción se relaciona con métodos para tratar o prevenir trastornos hematológicos mediante el suministro de 15-HEPE o composiciones del mismo.
MX2022012404A 2020-04-03 2020-04-03 Composiciones que comprenden 15-hepe para tratar o prevenir trastornos hematológicos y/o enfermedades relacionadas. MX2022012404A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2020/059682 WO2021197639A1 (en) 2020-04-03 2020-04-03 Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases

Publications (1)

Publication Number Publication Date
MX2022012404A true MX2022012404A (es) 2023-02-09

Family

ID=70189967

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012404A MX2022012404A (es) 2020-04-03 2020-04-03 Composiciones que comprenden 15-hepe para tratar o prevenir trastornos hematológicos y/o enfermedades relacionadas.

Country Status (10)

Country Link
EP (1) EP4125854A1 (es)
JP (1) JP2023528562A (es)
KR (1) KR20220163468A (es)
CN (1) CN115715192A (es)
AU (1) AU2020440809A1 (es)
BR (1) BR112022020012A2 (es)
CA (1) CA3179158A1 (es)
IL (1) IL297114A (es)
MX (1) MX2022012404A (es)
WO (1) WO2021197639A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220133669A1 (en) * 2020-10-30 2022-05-05 Ds Biopharma Limited Pharmaceutical compositions comprising 15-hetre and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001238468B2 (en) * 2000-02-16 2006-07-06 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators
US7485323B2 (en) 2005-05-31 2009-02-03 Gelita Ag Process for making a low molecular weight gelatine hydrolysate and gelatine hydrolysate compositions
GB201213484D0 (en) * 2012-07-30 2012-09-12 Dignity Sciences Ltd Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
CN108025181A (zh) * 2015-07-21 2018-05-11 艾菲穆恩有限公司 用于治疗或预防癌症和神经疾病的包括15-hepe的组合物

Also Published As

Publication number Publication date
AU2020440809A1 (en) 2022-11-10
WO2021197639A1 (en) 2021-10-07
IL297114A (en) 2022-12-01
CA3179158A1 (en) 2021-10-07
JP2023528562A (ja) 2023-07-05
CN115715192A (zh) 2023-02-24
KR20220163468A (ko) 2022-12-09
BR112022020012A2 (pt) 2022-12-13
EP4125854A1 (en) 2023-02-08

Similar Documents

Publication Publication Date Title
MX2021009246A (es) Inmunomoduladores, composiciones y metodos de los mismos.
PH12020551062A1 (en) 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways
PH12020551425A1 (en) Rimegepant for cgrp related disorders
MX2023001876A (es) Derivados de rapamicina.
MX2018003569A (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
MX2023005636A (es) Inhibidores de bcl6 derivados de bencimidazolona.
MX2021010888A (es) Derivados heteroaromaticos y aromaticos heterobiciclicos para el tratamiento de trastornos relacionados con ferroptosis.
MX2023001450A (es) Composiciones y metodos para la inhibicion de la expresion de plp1.
CR20220207A (es) Compuestos terapéuticos y métodos de uso
MX2019007088A (es) Derivados de la pirimidin enona tricíclica para la inhibición de rory y otros usos.
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
PH12021550872A1 (en) Therapeutic compounds
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
MX2020000523A (es) Compuestos de isocromano y usos de los mismos.
MX2018008903A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
CR20220570A (es) Composiciones que comprenden nanopartículas, método de elaboración y usos de las mismas
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
CR20220160A (es) Derivados de piridazin-3(2h)-ona fusionados con azol
MX2020012281A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
WO2022218941A3 (en) Compositions and methods for inhibiting ketohexokinase (khk)
MX2022014924A (es) Moduladores de il-17a.
MX2022014925A (es) Moduladores de il-17a.
CR20230474A (es) Anticuerpos anti-cd19 y estructuras car-t
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.